Metoprolol Succinate Dosing Guidelines

General Dosing

The maximum recommended daily dose of metoprolol succinate is 200 mg once daily, as recommended by the European Society of Cardiology and the American Heart Association 1, 2
Metoprolol succinate is available as an extended-release (ER) formulation that allows for once-daily dosing, according to the American College of Cardiology 2
The typical starting dose is 25-50 mg once daily, with gradual titration to the target dose, as suggested by the European Heart Journal and the American Heart Association 1, 2

For heart failure patients, the recommended initial dose is 12.5-25 mg once daily, with a target dose of 200 mg once daily, as recommended by the European Society of Cardiology and the American Heart Association 1, 2
Dose may be doubled every 1-2 weeks if the preceding dose was well tolerated, according to the European Heart Journal 1
In clinical trials, the mean dose achieved was 159 mg daily, as reported in the journal Circulation 2

For hypertension, the usual dose range is 50-400 mg once daily, as suggested by the American College of Cardiology 3
Metoprolol succinate can be used as monotherapy or in combination with other antihypertensives, such as diuretics, according to the Journal of the American College of Cardiology 4

After initial IV therapy in acute MI, oral metoprolol is typically started at 50 mg every 6 hours for 48 hours, as recommended by the American Heart Association 5
Maintenance dose after MI is 100 mg twice daily, according to the American Heart Association 5

During titration, monitor for evidence of heart failure symptoms, fluid retention, hypotension, and symptomatic bradycardia, as suggested by the European Heart Journal 1
If worsening symptoms occur, consider increasing diuretics or ACE inhibitors before reducing beta-blocker dose, according to the European Heart Journal 1

Avoid initiating in patients with signs of heart failure, low output state, or increased risk for cardiogenic shock, as recommended by the American Heart Association 5
Do not use in patients with PR interval >0.24 seconds, second or third-degree heart block, active asthma, or reactive airways disease, according to the American Heart Association 5
Use cautiously in patients with bronchospastic airway disease requiring a beta-blocker, as suggested by the American College of Cardiology 4

Metoprolol tartrate is an immediate-release formulation that requires twice-daily dosing, as stated by the Circulation journal 6

The American College of Cardiology/American Heart Association guidelines recommend metoprolol succinate sustained release to be administered at 200 mg once daily for heart failure with reduced ejection fraction, with a strength of evidence based on clinical trials 7

The American College of Cardiology recommends metoprolol tartrate (IR) requires twice-daily dosing (typically 25-100 mg twice daily) due to shorter half-life 8

The European Heart Journal suggests starting with a low dose of 12.5-25 mg once daily and titrate gradually by doubling the dose every 1-2 weeks if the preceding dose was well tolerated 9
The European Heart Journal recommends target dose is typically 200 mg once daily for heart failure patients, with initial dose 12.5-25 mg once daily 9

The European Heart Journal advises monitoring for evidence of heart failure symptoms, fluid retention, hypotension, and symptomatic bradycardia during titration 9
The European Heart Journal suggests if symptoms worsen, first increase diuretics or ACE inhibitors, temporarily reduce beta-blocker dose if necessary, and in case of hypotension, first reduce vasodilators 9

The European Heart Journal warns to never abruptly discontinue either formulation as this may precipitate angina, myocardial infarction, or arrhythmias 9
The European Heart Journal advises avoiding initiating in patients with decompensated heart failure, requiring IV inotropic therapy, or with marked fluid retention, and for patients with severe heart failure (NYHA Class III/IV), specialist referral is recommended for beta-blocker initiation 9

The American College of Cardiology and American Heart Association guidelines support the use of metoprolol succinate, a sustained-release formulation, which is designed for once-daily administration and has been proven to reduce mortality in heart failure, as demonstrated in clinical trials 10, 11, 12
The sustained-release metoprolol succinate formulation is the specific preparation that demonstrated mortality reduction in clinical trials, while short-acting metoprolol tartrate showed lesser effectiveness 10, 11, 12

The American College of Cardiology and American Heart Association guidelines specifically note that metoprolol tartrate dosed at 50 mg twice daily is commonly prescribed, but this was neither the dose nor formulation used in trials that showed mortality reduction, and using metoprolol succinate twice daily would be inappropriate dosing that deviates from evidence-based practice 10, 11, 12

The American Heart Association recommends metoprolol succinate for heart failure with reduced ejection fraction, as it has been proven to reduce mortality by 34% in the MERIT-HF trial, with a 41% reduction in sudden death and 49% reduction in death from worsening heart failure 13
The American College of Cardiology recommends metoprolol succinate as the preferred formulation for heart failure with reduced ejection fraction, as metoprolol tartrate has shown inferior outcomes compared to carvedilol in the COMET trial 13, 14, 15
For hypertension, the European Society of Cardiology recommends metoprolol tartrate 25-100 mg twice daily, which is equivalent to metoprolol succinate 50-200 mg once daily in terms of beta-blocking activity 16

The American Heart Association recommends a target dose of 200 mg once daily for metoprolol succinate in heart failure patients, with a starting dose of 12.5-25 mg once daily and titration every 1-2 weeks if tolerated 17
The European Society of Cardiology recommends metoprolol tartrate 25-100 mg twice daily for hypertension or angina, which is not the formulation proven to reduce mortality in heart failure 16

The American College of Cardiology recommends monitoring for symptomatic hypotension (systolic BP <85 mmHg) during uptitration of metoprolol succinate in heart failure patients 14
The American Heart Association recommends monitoring for worsening renal function during uptitration of metoprolol succinate in heart failure patients 15